BACKGROUND

Sickle cell disease has been studied for decades because of the devastating effects it causes for those suffering from it. The genes have been identified, the pathophysiology explained it detail, and proposed reasons as to why the mutation exist in the first place. Treatment has always consisted of pain management as this is primarily a PAIN MANAGEMENT disease. Developments have been discovered to target the root of the disease, so that hopefully pain may be secondary thought, and sickle cell disease can be controlled.

Patient is a 25 year old male with sickle cell disease. He has recurrent sickle cell crisis events in which he is hospitalized Any astute biology student knows the basic about 1-3 times a month for management. His typical hospital mechanism of the disease. Chromosome 11 that management therapies consist of IV narcotics, hypotonic fluids codes for the Glutamate (GAG codon) has a point (as to not worsen the sickling of cells), and the American Red mutation to translate to Valine (GTG codon). This Cross performing an exchange transfusion to keep his HgbS to allows for the tetramer hemoglobin molecule to misless than 55%. The conglomeration of all the misshapen fold. hemoglobin molecules will cause the erythrocyte to **PMH**: Hgb SC Disease, Obesity, MDD, Opiate Dependence, take on a sickling appearance under microscopic Pulmonary Embolism, Syringoma observation (hence the name).

PSH: priapism decompression These now sickled cells create chaos at the microscopic environment. The capillary beds are MED: carvedilol 3.125mg BID, duloxetine 60mg, LMWH constantly becoming clogged and preventing 150units, fentanyl TD 75mcg TD, gabapentin 600mg TID, perfusion to the subsequent tissues. The areas of hydromorphone 8mg q6hr, hydroxyurea 1000mg, hydroxyzine the body that have the highest amount of capillary 20mg QID, ibuprofen 800mg TID, narcan 0.4mg PRN, beds are skeletal muscle, brain, heart, lung, liver, topiramate 200mg BID, tramadol 100mg q6hr Knowing this factoid, the spleen and kidney. complications are then easily explainable. Skeletal **ALL**: nuts muscle not being perfused creates pain from lack of oxygenation. The brain starving for oxygen leads to **FAM**: mother (deceased from bariatric surgery, DMT2) a decreased seizure threshold. The heart with brother (GSW) decreased blood flow creates the "acute chest sister (deceased from polysubstance abuse, Bipolar) syndrome". The lungs can suffer from pulmonary sister (sickle cell anemia) infarct in situ. The liver eventually becomes cirrhotic. These patient's are functionally asplenic by the time **SOC**: denies tobacco, denies etoh, denies illicit drug use they are teenagers (hence they need their encapsulated bacteria vaccines). And finally, under VITALS: 130s/60s mmHg – 90s bpm – 20 rpm – 95% RA decreased oxygenation, acidic and hyperosmolar environment, the renal papillae will necrose creating **PE**: pertinent positive of webbed fingers gross hematuria.

A NOVEL APPROACH FOR SICKLE CELL TREATMENT


<u>William Heppenstall</u>, DO¹, williamhep@pcom.edu, Kenneth Hoellein, MD² 1. Department of Internal Medicine, (Philadelphia College of Osteopathic Medicine, Philadelphia, PA) 2. Division of Internal Medicine, (Philadelphia College of Osteopathic Medicine, Philadelphia, PA)



PATIENT PRESENTATION

Baseline Hgb in the 9's **Baseline Retic Count 2's**

Voxelotor is a novel approach for sickle cell disease treatment. It is a molecule allosterically binds to the site where the hemoglobin molecule inappropriately folds. This binding prevents the hemoglobin from sickling the entire cell.



The drug has been objectively studied for the effects of bone marrow turnover (aka reticulocyte count), hemoglobin levels, and hemolysis markers (ex. LDH and bilirubin). This patient had the expected results of his reticulocyte count increasing from his baseline 2 to 6 and his hemoglobin increasing from his baseline 9's to 12's.

But from a humane perspective, how is the patient clinically? He is still on his current doses of his narcotics BUT his hospitalizations have DECREASED from 1-3 times a month to about once every 3 months!!! This is not the cure for sickle cell disease yet, but it is definitely a step in the right direction.

REFERENCES

https://www.genome.gov/sites/default/files/media/images/6.1.4.6 3_sickle_cell_blood_cell.jpg https://www.researchgate.net/profile/James-Partridge-3/publication/312643776/figure/fig1/AS:614312305500200@15 23474875791/figure-fig1_Q320.jpg https://oxbryta.com/?utm_source=google&utm_medium=cpc&ut m_campaign=%7Bcampaign%7D%3B11794498743%3B&utm_ content=507432839031%3B117128407880&utm_term=%2Boxb ryta%20voxelotor&gclid=CjwKCAjwpKCDBhBPEiwAFgBzj9318v 6VdiZV2NB59F8kWqKUv8VJkR76IaNesOq2pktB7iAnFJ9C9Bo CxxkQAvD_BwE&gclsrc=aw.ds

NEW FORM OF TREATMENT